Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Summary

This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients. A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.

Timeline

Start

2026-08

Primary completion

2027-03

Completion

2027-03

Drugs

Indications